ALung Technologies, Inc.
Hospitals
Hemolung provides dialysis-like technology with expected benefits to clinical outcomes, patient quality of life, and the bottom line
A superior alternative to invasive mechanical ventilation, the dialysis-like Hemolung system effectively supplements lung function through a single, small catheter, removing up to 50% retained carbon dioxide from the blood, while also administering oxygen.
Hemolung improves clinical outcomes
Because the Hemolung eliminates the need for intubation, sedation and tracheostomies, patients will benefit from the reduced length of stay in ICU, reduced incidence of ventilator assisted pneumonia (VAP), reduced airway wall damage, and the elimination of the ventilator weaning period.
Hemolung improves patient quality of life
By avoiding sedation, patients can eat, drink and talk while on the Hemolung, allowing them to rest and recover more quickly with the support of their family and friends.
Hemolung reduces cost of care
With ICU care estimated to cost up to $7,000 per day, the Hemolung is expected to reduce cost by reducing the length of stay in the ICU. Further cost savings are realized through the elimination of sedation costs, and a reduction in adverse outcomes such as VAP - estimated at $125,000 per incident.